Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Sold as Sanctura, Sanctura Xr. Every FDA application for this active ingredient: 2 branded and 12 generic.
As of Nov 15, 2026, FDA lists 14 applications for Trospium Chloride (sold as Sanctura, Sanctura Xr), first approved May 28, 2004, with 0 new uses approved and 0 published complete response letters.
First approved: May 28, 2004
Applications: 14
New uses approved: 0
Complete response letters: 0
Medicare spending, 2025: $54.2M
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Trospium Chloride
Part D
$32.3M
+33%
184,196
Trospium Chloride ER
Part D
$22.0M
-2%
44,163
What Pharmacies Pay
Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change
TROSPIUM CHLORIDE 20 MG TABLET: $0.207 per unitGeneric · -19% in a year
TROSPIUM CHLORIDE ER 60 MG CAP: $1.61 per unitGeneric · -15% in a year
Clinical Trials
31 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
Allergan
Apotex